Contec to Provide Virtual Contamination Control Assessments
The virtual assessments will address problems, issues, and questions customers have about their environments and operations.
Contec announced on Nov. 30, 2020 that it is now offering virtual contamination control assessments (CCA) to address problems, issues, and questions customers have about their environments and operations.
According to a company press release, Contec’s CCA options include:
- CCA Consult: virtual meeting, discussion, and interviews with one or more Technical Services Group (TSG) experts
- CCA Remote: remote assessment with video tour or stationary video observation, with one or more TSG experts
- CCA In-person: complete onsite assessment with one TSG expert.
“Contec has grown in our efforts to provide education, training, and best practice recommendations for the most critical environments,” said Dave Nobile, TSG manager, Contec, in the press release. “We have been providing in-person assessments for years, however, virtual offerings are needed now more than ever. We are excited to now offer the same benefits of our in-person assessments to our customers in an effective, safe, and virtual way.”
Source: Contec
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
